All In Biotech

Drug Trial Radar · NCT01465802

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

ARCHER 1042: A PHASE 2 STUDY OF DACOMITINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (POST-CHEMOTHERAPY OR SELECT FIRST LINE PATIENTS) TO EVALUATE PROPHYLACTIC INTERVENTION ON DERMATOLOGIC AND GASTROINTESTINAL ADVERSE EVENTS AND PATIENT REPORTED OUTCOMES

Last checked: Nov 20, 2026Latest source record: Jan 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

236

Actual

Start

Dec 26, 2011

Primary completion

May 18, 2015

Study completion May 18, 2015

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 7, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the impact of prophylactic treatment on the incidence of adverse events in advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent. To assess the impact of an interrupted dacomitinib dosing schedule in Cycle 1 on the incidence of adverse events in first-line advanced NSCLC patients with an EGFR mutation (HER-1 mutation, HER-2 mutation or HER-2 amplification).

Conditions

  • Non Small Cell Lung Cancer (NSCLC)

Interventions

  • DacomitinibDrug

    Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent

  • DacomitinibDrug

    Dacomitinib 45 mg orally daily on a continuous schedule for the first 10 days in Cycle 1, followed by 4 days off treatment, followed by continuous daily dosing until disease progression, toxicity, death or withdrawal of consent

  • DoxycyclineDrug

    Doxycycline or Doxycycline placebo BID for 4 weeks

  • ProbioticDrug

    VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)

  • Alclometasone creamDrug

    Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Select Dermatologic Adverse Events of Interest (SDAEI) (All Causality, All Grade) in the First 8 Weeks of Treatment by Treatment Arm for Cohort ITime frame: First 8 Weeks of Treatment
  2. Percentage of Participants With SDAEI (All Causality, Grade Greater Than or Equal to [≥] 2) in the First 8 Weeks of Treatment by Treatment Arm for Cohort ITime frame: First 8 Weeks of Treatment
  3. Mean Change From Baseline (Cycle 1 Day 1) Skindex-16 Scale Scores (Total Score, Symptoms Score, Emotion Score, and Functioning Score) by Treatment Arm for Cohort ITime frame: First 8 Weeks of Treatment
  4. Percentage of Participants With Diarrhea AEs (All Causality, All Grade and Grade ≥2) in the First 8 Weeks of Treatment for Cohort IITime frame: First 8 Weeks of Treatment
  5. Mean Change From Baseline (Cycle 1 Day 1) Modified Oral Mucositis Daily Questionnaire (OMDQ) Scores (Mouth and Throat Soreness Categories and Scale, and Diarrhea Categories and Scale) for Cohort IITime frame: Cycles 1, 2, 3, 4, 5, and 6, EoT and Follow-up
  6. Percentage of Participants With SDAEI (All Causality, All Grade) in the First 8 Weeks of Treatment for Cohort IITime frame: First 8 Weeks of Treatment
  7. Percentage of Participants With SDAEI (All Causality, Grade ≥2) in the First 8 Weeks of Treatment for Cohort IITime frame: First 8 Weeks of Treatment
  8. Mean Change From Baseline (Cycle 1 Day 1) Skindex-16 Scale Scores (Total Score, Symptoms Score, Emotion Score, and Functioning Score) for Cohort IITime frame: Cycles 1, 2, 3, 4, 5, and 6, EoT and Follow-up
  9. Mean Area Under the Plasma Concentration Time Curve From 0 to 24 Hours (AUC0-24) and From 0 to 120 Hours (AUC0-120) for Dacomitinib and Its Metabolite PF-05199265 on Cycle 1 Days 10 to 15 for Cohort IIITime frame: Cycle 1 Day 10: Pre-dose and 2, 4, 6, 24, 48, 72, 96, and 120 hours post-dose (the 120 hour sample was obtained on Day 15 pre-dose).
  10. Mean Maximum Observed Plasma Concentrations (Cmax) for Dacomitinib and Its Metabolite PF-05199265 on Cycle 1 Days 10 to 15 for Cohort IIITime frame: Cycle 1 Day 10: Pre-dose and 2, 4, 6, 24, 48, 72, 96, and 120 hours post-dose (the 120 hour sample was obtained on Day 15 pre-dose).
  11. Median Time of Occurrence of Cmax (Tmax) for Dacomitinib and Its Metabolite PF-05199265 on Cycle 1 Days 10 to 15 for Cohort IIITime frame: Cycle 1 Day 10: Pre-dose and 2, 4, 6, 24, 48, 72, 96, and 120 hours post-dose (the 120 hour sample was obtained on Day 15 pre-dose).

Locations

81 sites in 2 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • St. Jude Heritage Healthcare

    Fullerton, California

  • UCLA Hematology Oncology

    Irvine, California

  • UC San Diego Medical Center - La Jolla

    La Jolla, California

  • UC San Diego Moores Cancer Center - Investigational Drug Services

    La Jolla, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Drug Management Only: UCLA West Medical Pharmacy

    Los Angeles, California

  • Drug Management Only: UCLA West Medical Pharmacy Attn: Steven L. Wong, Pharm.D.

    Los Angeles, California

  • Drug Management Only: UCLA West Medical Pharmacy

    Los Angeles, California

  • Drug Managment Only: UCLA West Medical Pharmacy

    Los Angeles, California

  • Regulatory Management Only TRIO-US Central Administration

    Los Angeles, California

  • Regulatory Management Only: TRIO-US Central Administration

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • UCLA Hematology Oncology

    Los Angeles, California

  • Westwood Bowyer Clinic

    Los Angeles, California

  • UCLA/Pasadena HealthCare

    Pasadena, California

  • UC San Diego Medical Center - Hillcrest

    San Diego, California

  • Coastal Integrative Cancer Care

    San Luis Obispo, California

  • SANSUM Clinic

    Santa Barbara, California

  • Cancer Center of Santa Barbara with SANSUM Clinic

    Santa Barbara, California

  • Central Coast Medical Oncology Corporation

    Santa Maria, California

  • UCLA Hematology Oncology

    Santa Monica, California

  • UCLA Santa Monica Medical Center & Orthopaedic Hospital

    Santa Monica, California

  • Cancer Center of Santa Barbara with SANSUM Clinic

    Solvang, California

  • City of Hope South Pasadena Cancer Center

    South Pasadena, California

  • UCLA/Santa Clarita Valley Cancer Center

    Valencia, California

  • UCLA Cancer Center

    Westlake Village, California

  • Kaiser Permanente Colorado - Franklin

    Denver, Colorado

  • St. Mary's Hospital Regional Cancer Center

    Grand Junction, Colorado

  • Kaiser Permanente Colorado - Rock Creek

    Lafayette, Colorado

  • Kaiser Permanente Colorado - Lonetree

    Lonetree, Colorado

  • Michael and Dianne Bienes Comprehensive Cancer Center, Holy Cross Hospital

    Fort Lauderdale, Florida

  • Memorial Cancer Institute

    Hollywood, Florida

  • Cancer Care of North Florida, PA

    Lake City, Florida

  • Memorial West Cancer Institute

    Pembroke Pines, Florida

  • University Cancer & Blood Center, LLC

    Athens, Georgia

  • Summit Cancer Care,PC

    Savannah, Georgia

  • Summit Cancer Care, PC

    Savannah, Georgia

  • Rush University Medical Center, Division of Hematology & Oncology

    Chicago, Illinois

  • Ships Drugs to: Emmanuel Semmes, RPh (or Ami Patel, Pharm D) University of Chicago

    Chicago, Illinois

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.